What are the key unmet medical needs remaining for people with severe epilepsy?
Improving quality of life for people with severe epilepsy: focus on comorbidities
Audience questions and close
Video Player Controls:
Professor Ley Sander discusses the challenges and unmet needs that people with epilepsy still face today. Also focusing on what more can be done to improve the lives of people with severe epilepsy.
Please Select A Video:
Overview & Learning Objectives
Despite the availability of a wide variety of anti-epileptic drugs, there is still a clear unmet medical need; it is estimated that in 30–40% of all people with epilepsy, the disease is refractory to treatment, and patients continue to experience seizures.1
Consequently, people with uncontrolled severe epilepsy experience significant impact on quality of life and activities of daily living.2
For this touchLIVE MEETING webinar, three leading experts will be discussing key issues in the treatment and management of severe epilepsy, focussing on:
- Recognizing unmet medical needs in severe epilepsy beyond control of clinical seizures
- Evaluating the latest translational research and clinical findings for patients with frequent seizures, and their carers and family
- Reviewing how lessons on patient and caregiver support can be incorporated into daily practice
After watching this activity, you should be able to:
- Recognise the unmet medical needs in severe epilepsy beyond control of clinical seizures
- Evaluate the latest translatable and clinical findings for patients with frequent seizures, and their carers and family
- Review how lessons on patient and caregiver support from the COVID-19 pandemic can be incorporated into daily practice
Faculty & Disclosures
Professor Ley Sander
Professor of Neurology and Clinical Epilepsy, National Hospital for Neurology & Neurosurgery, Queen Square, London, UK
Ley Sander is Professor of Neurology and Clinical Epilepsy and Honorary Consultant Neurologist with a specialist interest in epilepsy. read more
In this role, he has approximately 1,200 people with epilepsy under his neurological care. He heads the Department of Clinical and Experimental Epilepsy at the National Hospital for Neurology & Neurosurgery and is the Medical Director of the Chalfont Centre for Epilepsy in Buckinghamshire. Ley Sander is also the Scientific Director of Stichting Epilepsie Instellingen Nederland in Heemstede, the Netherlands. He qualified in medicine at the University of Parana in Curitiba, Brazil and then completed his specialist training in neurology at St Thomas Hospital and at the National Hospital for Neurology and Neurosurgery in London. He obtained his PhD in clinical neurosciences at the University of London and is an elected fellow of the Royal College of Physicians.
Professor Sander has received research grants from Medtronic and UCB, received honoraria as a speaker in virtual and presential events sponsored by Arvelle Therapeutics, Eisai, GW Pharmaceuticals Plc, Novartis, UCB and Zogenix, and for participation on advisory boards for Arvelle, UCB and Zogenix. Professor Sander has, or his department has, undertaken, or are undertaking, studies funded by research grants from Medtronic and UCB. He has not, nor has any members of his family, owned shares or equities in pharmaceutical or medical device companies.
Dr Kerstin Alexandra Klotz
Paediatric Neurologist, University of Freiburg, Freiburg, Germany
Dr. Alexandra Klotz is head of the pediatric epileptology section of the Department of Neuropediatrics and Muscle Disorders at the University Hospital Freiburg, Germany. read more
She is also a fellow of the Berta Ottenstein program, a three year research fellowship. Dr. Klotz clinical as well as scientific work is the management of rare and difficult to treat epilepsies in children. Her main research interests are Cannabinoids in the treatment of epilepsy and comorbidities in patients with hypothalamic hamartoma and other epilepsies. Dr. Klotz is member of the European Reference Network EpiCARE and of the Freiburg Center of rare diseases. She is also a principal investigator on different clinical trials to advance the development of new treatment options for children with drug-resistant epilepsies.
Dr Klotz has received speaker fees and served on advisory boards for EISAI, GW Pharmaceuticals Plc., Zogenix, PTC Therapeutics GmbH Germany and Neuraxpharm.
Prof. Pasquale Striano
Associate Professor, Università degli Studi di Genova, Genova, Italy
Prof. Striano is actively involved in research projects in Italy, Europe and worldwide. He is a board member of Italian League Against Epilepsy (LICE), a scientific association that is focused on promoting knowledge of epilepsy among people and among physicians to improve the care of patients. The collaborative network of LICE is actively working on both International and European projects. read more
Prof. Striano is an associate partner of the EUROEPINOMICS consortium for the study of genetic epilepsies through next-generation sequencing techniques. The project involves the sequencing of coding regions of the genome of patients with undiagnosed epileptic encephalopathies and familiar forms with dominant or recessive inheritance. Prof. Striano has received The International League Against Epilepsy Young Investigator Award at the European Congress of Epileptology, London, November 2012. From 2013, he has been a member of the Pediatric Committee of Italian Medicines Agency.
Prof. Striano has received speaker fees and has participated in advisory boards for Biomarin, GW Pharmaceuticals and Zogenix, and has received research funding from Eisai ENECTA BV, GW Pharmaceuticals Plc and Kolfarma Srl.
- Laxer KD, Trinka E, Hirsch LJ, et al. Epilepsy Behav, 2014;37:59-70.
- Berto P, Pharmacoeconomics, 2002;20:1039-59.
- Sperling MR, O'Connor MJ. Ann Neurol 1990;28(3):320-8.